HAE Clinical Trials in London
19 recruitingLondon, United Kingdom
Showing 1–19 of 19 trials
Recruiting
Phase 3
STOP-HAE: A Phase 3 Study of ADX-324 in HAE
Hereditary AngioedemaHereditary Angioedema - Type 1Hereditary Angioedema - Type 2+1 more
ADARx Pharmaceuticals, Inc.90 enrolled51 locationsNCT06960213
Recruiting
Phase 3
Long-Term, Open-label Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE
Hereditary Angioedema (HAE)
Pharvaris Netherlands B.V.170 enrolled62 locationsNCT06679881
Recruiting
Phase 3
A Study of Navenibart in Participants With Hereditary Angioedema
Hereditary Angioedema (HAE)
Astria Therapeutics, Inc.145 enrolled87 locationsNCT06842823
Recruiting
A Study of Lanadelumab in Children With Hereditary Angioedema (HAE) in Multiple Countries
Hereditary Angioedema (HAE)
Takeda40 enrolled24 locationsNCT07251933
Recruiting
Phase 3
Phase 3 Extension Study of ADX-324 in Participants With Hereditary Angioedema (HAE)
Hereditary Angioedema (HAE)Hereditary Angioedema - Type 1Hereditary Angioedema - Type 2+1 more
ADARx Pharmaceuticals, Inc.90 enrolled48 locationsNCT07428499
Recruiting
Phase 1
A Research Study Looking at How Different Doses of Study Medicine (Inno8) Work in the Body of People With Haemophilia A
Haemophilia A
Novo Nordisk A/S30 enrolled33 locationsNCT07220564
Recruiting
Not Applicable
iCorMicA - Stratified Medicine in Angina
Coronary Artery DiseaseCoronary Microvascular Dysfunction (CMD)Angina, Stable+7 more
NHS Greater Glasgow and Clyde1,500 enrolled39 locationsNCT04674449
Recruiting
Phase 1
A Study of AZD2962, an IRAK4 Inhibitor (IRAK4 [a Body Protein] Blocker), in Participants With Haematologic Neoplasms (Blood Cancers)
Haematologic Neoplasms
AstraZeneca72 enrolled21 locationsNCT07064122
Recruiting
Not Applicable
Study of Lesion-Specific Invasive Haemodynamic Angina Thresholds
Coronary Artery Disease (CAD)Angina, StableIschaemic Heart Desease
Imperial College London60 enrolled6 locationsNCT07386418
Recruiting
Phase 1
A Phase 1 Study to Assess STP938 as a Monotherapy in Adults With High Risk Essential Thrombocythaemia
Essential Thrombocythaemia
Step Pharma, SAS20 enrolled13 locationsNCT06786234
Recruiting
Phase 1Phase 2
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
Acute Myeloid LeukemiaNon-Hodgkin LymphomaMultiple Myeloma+3 more
CellCentric Ltd.250 enrolled39 locationsNCT04068597
Recruiting
Phase 2Phase 3
DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With HER2 Amplification or Activating Mutations
Ovarian NeoplasmsColorectal NeoplasmsUrinary Bladder Neoplasm+8 more
Cancer Research UK30 enrolled27 locationsNCT05786716
Recruiting
Phase 2Phase 3
DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.
MelanomaCarcinoma, Non-Small Cell LungOvarian Neoplasms+9 more
Cancer Research UK30 enrolled16 locationsNCT05768178
Recruiting
Phase 2Phase 3
DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Paediatric and Teenage/Young Adult Patients With ROS1 Gene Fusion-Positive Cancers.
MalignancyMelanomaCancer+8 more
Cancer Research UK30 enrolled27 locationsNCT05770544
Recruiting
Phase 2Phase 3
DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage/Young Adult Patients With ALK Positive Cancers
CancerRenal Cell CarcinomaLymphoma+8 more
Cancer Research UK30 enrolled27 locationsNCT05770037
Recruiting
Phase 2Phase 3
DETERMINE Trial Treatment Arm 06: Capmatinib in Adult Patients With Cancers Harbouring MET Dysregulations
MalignancyGastric CancerSoft Tissue Sarcoma+8 more
Cancer Research UK30 enrolled17 locationsNCT06988475
Recruiting
Phase 2Phase 3
DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening Protocol
Haematological MalignancySolid Tumour
Cancer Research UK825 enrolled27 locationsNCT05722886
Recruiting
Efficacy, Safety & Utilisation of Nuwiq, Octanate and Wilate in Previously Untreated & Minimally Treated Haemophilia A Patients
Haemophilia A
Octapharma200 enrolled55 locationsNCT03695978
Recruiting
Renal Perfusion and the Development of AKI Following Traumatic Injury
AKI - Acute Kidney InjuryTraumatic Haemorrhagic ShockAKI (Acute Kidney Injury) Due to Trauma
King's College Hospital NHS Trust20 enrolled1 locationNCT06917053